A Pilot Study of Adjuvant Pembrolizumab After Lung Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Early Stage Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase 0
Latest Information Update: 26 Feb 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 21 Feb 2019 Status changed from not yet recruiting to recruiting.
- 18 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Feb 2019.
- 04 Oct 2018 Planned initiation date changed from 19 Sep 2018 to 1 Dec 2018.